Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Aumolertinib in First-line Advanced NSCLC with EGFR 21L858R Mutation
NCT06102928Recruiting
- Sponsor
- Kunming Medical University
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anlotinib and almonertinib in non-small cell lung cancer (NSCLC), sponsored by Kunming Medical University. Primary endpoint: Median Progression-Free Survival up to 2 years. Started Oct 2023; status: recruiting.
02
Drugs
anlotinibalmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06102928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102928.